Enhanced Function of Induced Pluripotent Stem Cell-Derived Endothelial Cells Through ESM1 Signaling

Vilà-González, M., Kelaini, S., Magee, C., Caines, R., Campbell, D., Eleftheriadou, M., Cochrane, A., Drehmer, D., Tsifaki, M., O'Neill, K., Pedrini, E., Yang, C., Medina, R., McDonald, D., Simpson, D., Zampetaki, A., Zeng, L., Grieve, D., Lois, N., ... Margariti, A. (2018). Enhanced Function of Induced Pluripotent Stem Cell-Derived Endothelial Cells Through ESM1 Signaling. Stem Cells, 37(2), 226. Advance online publication. https://doi.org/10.1002/stem.2936

Published in:
Stem Cells

Document Version:
Publisher's PDF, also known as Version of record

Queen's University Belfast - Research Portal:
Link to publication record in Queen's University Belfast Research Portal

Publisher rights
Copyright 2018 the authors. This is an open access article published under a Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium, provided the author and source are cited.

General rights
Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The Research Portal is Queen’s institutional repository that provides access to Queen’s research output. Every effort has been made to ensure that content in the Research Portal does not infringe any person’s rights, or applicable UK laws. If you discover content in the Research Portal that you believe breaches copyright or violates any law, please contact openaccess@qub.ac.uk.

Open Access
This research has been made openly available by Queen's academics and its Open Research team. We would love to hear how access to this research benefits you. – Share your feedback with us: http://go.qub.ac.uk/oa-feedback
Enhanced Function of Induced Pluripotent Stem Cell-Derived Endothelial Cells through ESM1 Signalling

MARTA VILÀ-GONZÁLEZ,a † SOPHIA KELAINI,† a COREY MAGEE,a RACHEL CAINES,a DAVID CAMPBELL,a MAGDALINI ELEFTHERIADOU,a AMY COCHRANE,a DAIVANA DREHMER,a MARIANNA TSIFAKI,a KARLA O’NEILL,a EDDARDO PEDRINI,a CHUNBO YANG,a REINHOLD MEDINA,a DENISE MCDONALD,a DAVID SIMPSON,a ANNA ZAMPETAKI,a LINGFANG ZENG,b DAVID GRIEVE,a NOEMI LOIS,a ALAN WS TITT,a ANDRIANA MARGARITI,a

Key Words. ESM1 • reprogramming • endothelial cells • vascular disease • induced pluripotent stem cells

ABSTRACT

The mortality rate for (cardio)-vascular disease is one of the highest in the world, so a healthy functional endothelium is of utmost importance against vascular disease. In this study, human induced pluripotent stem (iPS) cells were reprogrammed from 1 ml blood of healthy donors and subsequently differentiated into endothelial cells (iPS-ECs) with typical EC characteristics. This research combined iPS cell technologies and next-generation sequencing to acquire an insight into the transcriptional regulation of iPS-ECs. We identified Endothelial cell-specific molecule 1 (ESM1) as one of the highest expressed genes during EC differentiation, playing a key role in EC enrichment and function by regulating connexin 40 (CX40) and eNOS. Importantly, ESM1 enhanced the iPS-ECs potential to improve angiogenesis and neovascularisation in in vivo models of angiogenesis and hind limb ischemia. These findings demonstrated for the first time that enriched functional ECs are derived through cell reprogramming and ESM1 signalling, opening the horizon for drug screening and cell-based therapies for vascular diseases. Therefore, this study showcases a new approach for enriching and enhancing the function of induced pluripotent stem cells from a very small amount of blood through ESM1 signalling, which greatly enhances their functionality and increases their therapeutic potential.

INTRODUCTION

The complications arising from macrovascular and microvascular disease can be a major source of mortality in diseases such as diabetes and cardiovascular disease (CVD) [1,2]. As a result, removing the causative insult is one of the primary strategies to repair endothelial cells (ECs) in vivo. However, when this approach is not adequate another important strategy is vascular regenerative medicine, which could repair and regenerate damaged cells including the generation of functional ECs for transplantation [3].

Induced pluripotent stem (iPS) cell-derived endothelial cells (iPS-ECs) have shown notable therapeutic potential in pre-clinical studies, which includes the ability to incorporate into and re-endothelialize damaged vasculature [3,4] as well as to inhibit neointimal and inflammatory responses to vascular injury [5]. In addition, they have shown great functional promise in providing opportunities for disease modelling [6,7]. Consequently, iPS cells in regenerative medicine show great potential today as they can be used to generate patient-specific cells and personalised therapies [8].
Even though there are many approaches in reprogramming methodology [9,10], many of the iPS cell generation mechanisms and their subsequent differentiation toward various cell lineages still remain relatively unclear. Moreover, prolonged culture of iPS-ECs populations can limit their clinical application and since they are not derived from intact blood vessels, they show an immature phenotype [11,12]. iPS-ECs generation efficiency has increased over the last years, resulting in nearly pure populations of endothelial-like cells [13]. However, these methods still present several limitations such as population heterogeneity transient endothelial phenotype and differentiation variability between cell lines. Recent studies have, thus, attempted to improve the aforementioned issues by improving the protocols for EC generation [14] and refining the acquisition of purer iPS-ECs populations through FACS [15] or EC progenitors through MACS [16,17]. However, more effort still needs to be made toward the understanding of the mechanisms that drive iPS-ECs differentiation in a well-defined and highly reproducible environment.

In the pursuit to understand the underlying mechanisms of the EC differentiation process, this research combined iPS cell technologies and next-generation sequencing to acquire a comprehensive insight into the transcriptional regulation of iPS-ECs differentiation. More specifically, the ultimate goal of this work was to identify endothelial lineage-enriched genes that have the potential to eventually increase iPS-ECs enrichment. To achieve that, human iPS cells were reprogrammed from 1 ml of blood using non-integrating reprogramming vectors from healthy donors in 7–10 days based on a fast and highly efficient approach. Up to six different donors were used to establish iPS cell lines for this study, which were then differentiated into iPS-ECs displaying typical EC characteristics. Subsequently, high-throughput RNA-sequencing (RNA-Seq) of iPS cells, iPS-ECs and a subset of primary endothelial cells (HUVECs) was implemented to undertake comparative transcriptome analyses. Out of the many genes, ESM1 emerged as a primary candidate due to its known implication in a variety of cell functions such as angiogenesis [18] and EC responses due to stress factors and disease [19]. As a result, we found that the Endothelial Cell-Specific Molecule 1 (ESM1) holds a key role in enrichment and improved function of iPS-ECs.

**METHODS**

Cell culture media, serum, and cell culture supplements were purchased from ATCC, Merck Millipore, LONZA, Sigma, BD, Reprocell and Thermo Fisher Scientific. Human aortic endothelial cells (HAoECs) were bought from Brennan and co. via Promocell, Ireland (C-12271). Magnetic beads were purchased from Miltenyi Biotec. Antibodies against ESM1 (ab103590), mCherry (ab125096), TRA-1-60 (ab16288), Lin28 (ab46020), eNOS (ab76198), KLF4 (ab72543) were purchased from Abcam. CD144 (VE-Cadherin) (ab33168 & STJ96234) and Oct4 (ab19857 & STJ72238) were purchased from Abcam or St John’s Laboratory. Antibodies against vWF (SC-8068) were purchased from Santa Cruz. VEGFR2 (MAB3571) and β-actin (MAB8929) were purchased from R&D. ZO-1 (40–2200) was purchased from Invitrogen. CD31/PECAM-1 (ab28364 & BBA7) was purchased from Abcam and R&D, while GAPDH (sc-25778 & ab8245) was purchased from Santa Cruz and Abcam. The secondary antibodies for immunostaining anti-mouse Alexa 568, and anti-rabbit Alexa 488, anti-rabbit Alexa 568, anti-goat Alexa 568, anti-goat alexa 488 were purchased from Thermo Fisher Scientific. The secondary antibodies for Western blotting were purchased from Abcam and Cell Signalling.

**Blood mononuclear cells isolation and expansion**

In this study iPS cell lines have been generated from at least 6 donors. Written informed consent was obtained from each donor before blood collection. Non-mobilised peripheral blood (1 to 20 ml) was collected by venepuncture in EDTA-coated 4 ml tubes. The blood was gradient-separated by layering it on Histopaque solution (1:1 ratio) and spinning for 30 minutes at 550gx at room temperature (break OFF). The mononuclear cells (MNCs) formed a buffy coat between the plasma layer and the Histopaque buffer layer, and were collected using a soft plastic pipette. After 3 washes with PBS, the cells were resuspended in 1 ml of MNC medium and plated at a density of 4 million cells/ml. After 7 days of expansion, changing the medium every three days, the cells were either cryopreserved or subjected to iPS cells reprogramming and EC differentiation (see also SI Appendix).

**RNA sequencing**

Cells were briefly washed with PBS and harvested using QIzol lysis buffer. Total mRNA and miRNA was extracted and purified using miRNAeasy (QIAGEN). The RNA concentration was determined using NanoDrop spectrophotometer and the integrity of the sample was assessed using Agilent RNA 6000 Nano Kit and Agilent 2,100 Bioanalyzer (Agilent Technologies). RNA sequencing libraries were prepared using a stranded KAPA RNA-Seq Kit with RiboErase (KapaBiosystems) according to the manufacturer’s instructions with 1 μg total RNA in 10 μl RNase-free water as an input. Libraries were sequenced on a NextSeq (Illumina) and reads mapped to the human reference genome (hg38), allowing up to 2 mismatches and up to 10 hits per read using the CLC Genomics Workbench 10.0.1 (https://www.qiagenbioinformatics.com). Reference sequences were annotated with genes and transcripts. Reference content was mapped to gene regions only. Expression values per gene or transcript were determined by total counts. An FDR-adjusted p-value of ≤0.05 was chosen to indicate statistical significance. Comparative gene expression data was filtered according to the defined fold change and FDR-adjusted p-value thresholds. Statistical analysis results were displayed as volcano plots, where −log10(p-values) are plotted against log2(fold change) for each feature. Hierarchical clustering of features (Manhattan distance; single linkage) was used to identify genes with similar expression patterns over the samples. K-mean clustering was also performed (number of partitions = 5; distance metric = Manhattan distance). For all RNA sequencing steps implemented in CLC, default settings were used, unless stated otherwise.

**Detailed Methods and Materials can be found in SI Appendix, Supplemental Experimental Procedures**
RESULTS

Efficient generation of integration-free iPS cells from peripheral blood mononuclear cells in 9 days

MNCs were isolated from healthy donor peripheral blood and expanded for 7 days before being successfully reprogrammed into iPS cells (Fig. 1A). MNCs were initially isolated from a starting amount of 20 ml of blood, followed by a scaling down procedure to 1 ml of blood. Because the efficiency of MNC reprogramming is lower than reprogramming from other cell sources, instead of only using the standard Yamanaka factors [20], we used the non-integrating episomal plasmid vectors pEB-C5 (overexpressing Oct4, Sox2, Klf4, c-Myc and Lin28), and pEB-Tg vector (overexpressing SV40 large T antigen) [21,22] to generate iPS cells in a fast and robust manner. Around day 9, typical iPS cell colonies with well-defined round limits were observed (Fig. 1B). Established iPS cell colonies from 1 ml of blood were determined to be pluripotent through the assessment of extensively characterised pluripotency-associated markers. iPS cell colonies stained positive for Oct4, TRA-1-60, Lin28 and CDy1 (Fig. 1B). Additional characterization using Real Time PCR (Fig. 1C) and immunoblotting (Fig. 1D) confirmed that iPS cells exhibit markedly enhanced expression of pluripotency markers at mRNA and protein levels. MNCs did not express these markers (Fig. 1C-D). Lastly, teratoma formation is widely accepted as the gold standard for defining bona-fide iPS cells. Following subcutaneous injection into severe combined immunodeficiency (SCID) mice, iPS cells formed tumour-like structures with components of all three germ cell layers - ectoderm, mesoderm and endoderm (Fig. 1E). Taken together, this fast and robust 9-day protocol successfully reprogrammed donor MNCs from as little as 1 ml of blood to fully pluripotent iPS cells using non-integrating methodology, whose pluripotent characteristics were confirmed on a number of levels.

Differentiation of human iPS cells to iPS-ECs

To differentiate iPS cells to iPS-ECs, cells were seeded on collagen IV-coated plates in EGM-2 media with bone morphogenetic protein 4 (BMP4), Activin A, 6-[[4-(4-Dichlorophenyl)-5-(5-methyl-1H-imidazol-2-yl)-2-pyridimidinyl]amino]ethyl]amino]-3-pyridinecarbonitrile (CHIR99021), and fibroblast growth factor 2 (FGF2). As it was expected, undifferentiated iPS cells were negative for EC markers such as CD31 prior to EC differentiation as flow cytometry data showed in Supplementary Figure S1A. After 48 hours, the medium was supplemented with vascular endothelial growth factor (VEGF), FGF2 and 4-[3-(2-Pyridinyl)-1H-pyrazol-4-yl]-quinoiline (LY364947) and was refreshed every other day. On day 6, positive selection of cells mediated by Magnetic Activation Cell Sorting (MACS) was performed, according to the expression of the endothelial-specific cell surface marker CD144, the most specific EC marker, and the cells were expanded and used for the experiments. From this point onwards, iPS-ECs positive for CD144 were cultured in conditions that would maintain the endothelial phenotype in the presence of VEGF and LY364947. The CD144 negative population was briefly characterised showing positive expression of the stromal marker CD90 (Supplementary Fig. S1C). In essence, this 6-day EC differentiation protocol (Fig. 2A) is both efficient and effective in generating iPS-EC lines. Following EC differentiation, the morphological appearance of the cells progressed away from the 3-dimensional organization of iPS cells to a flatter, more cobblestone-like morphology (Fig. 2B). In comparison to iPS cells, iPS-ECs displayed upregulation of the EC markers KDR, CD144 and eNOS at the mRNA level (Fig. 2C), confirming their progression toward the vascular lineage. This upregulation was progressive between days 0–6 of differentiation (Fig. 2C), while a decline was observed on day 9 (Supplementary Fig. S1B). Since there was a peak of EC marker expression on day 6 of differentiation and more than 80% of the cells were CD144+ (Fig. 2D), we performed MACS-mediated selection of CD144+ cells on day 6 and named the positively selected cells as iPS-ECs from this point on. Additional real time data also confirmed high levels of EC markers 3 days after CD144 selection (Fig. 2C). After this point, the cells were used for experiments and further immunoblotting experiments confirmed that, at the protein level, iPS-ECs had upregulated CD144 with concomitant downregulation of Oct4 (Fig. 2E). A key feature of mature ECs is their ability to form junctions. Such junctions permit adhesion and communication between ECs and as such, are involved in regulating processes including paracellular permeability, cell growth and angiogenesis [23]. Indeed, immunofluorescent staining of iPS-ECs confirmed their ability to form adherens and tight junctions, as evidenced by specific staining for CD144, CD31 and ZO-1 (Fig. 2F). iPS-ECs were positively stained using a low-density lipoprotein uptake assay, in which cells took up Acetylated (Ac)-LDL (Fig. 2F). When seeded onto Matrigel, iPS-ECs formed capillary-like structures in vitro, which were positively stained with CD144 (Fig. 2F). Overall, this EC differentiation protocol provides a robust method to produce populations of iPS-ECs.

A genome-wide shift away from pluripotency

To gain a detailed insight into the molecular changes that occur following the EC differentiation of iPS cells, RNA-Seq (RNA-seq) was performed. Gene expression profiles were compared for iPS cells, iPS-ECs and Human Umbilical Vein Endothelial Cells (HUVECs) in at least three independent experiments. HUVECs were chosen as representative primary ECs. Generated RNA-Seq outputs were analysed using the CLC Genomics Workbench 10.0.1 (https://www.qiagenbioinformatics.com) to identify differential expression patterns. Count distributions were visualised using box plots. In line with data quality assessment, expression values were normalised. To explore similarities and differences between cell lines, hierarchical clustering of samples was undertaken, which indicated that replicates clustered together, as expected (Fig. 2G). Of note, iPS-ECs clustered more closely with HUVECs than with iPS cells, confirming that the transcriptional network pertaining to these stem cell-derived ECs has undergone a shift in expression profile away from pluripotency and toward a specialised EC population. A scatterplot depicts the overall gene expression changes between iPS cells and iPS-ECs (Supplementary Fig. S2A). To confirm that iPS-ECs were a committed cellular population, fold change values for key pluripotency markers were assessed. Their genetic shift away from pluripotency was evidenced by the significant downregulation of Nanog (−2.731; p = .00), Oct4 (−23.009; p = .00), Lin28A (−10.073; p = .00) and SOX2 (−71; p = 1.06x10−25) in iPS-ECs versus iPS cells (Supplementary Fig. S2B). This confirms that
the differentiation protocol implemented here successfully generated EC-like cells from iPS cells by overwriting the pluripotent profile of the starter cell population. Importantly, iPS-ECs’ transcriptomes reflect expression patterns that are closer to that of primary mature ECs.

**EC differentiation enriches for key endothelial characteristics and ESM1 signalling**

To obtain a more detailed insight into the endothelial qualities of iPS-ECs, differential expression patterns for EC lineage-specific markers were assessed. iPS-ECs displayed a unique gene expression profile that separated them from iPS cells. When analysing differential expression, data was filtered to include only genes that were differentially expressed at a defined significance level. To remove genes with low fold change values, a fold change threshold of ≥2 was considered to indicate differential expression. An FDR-adjusted p-value of ≤0.05 indicated statistical significance. Under these parameters, 3,495 genes were significantly upregulated in iPS-ECs compared to iPS cells. When compared with iPS cells, sequenc- ing confirmed that iPS-ECs displayed upregulation of endothelial markers, (Supplementary Fig. S3A & B). iPS-ECs also demonstrated significant upregulation of EC-specific signalling (Supplementary Fig. S3A & B). Interestingly, a number of genes that were upregulated in iPS-ECs, including PTX3 and GDF5 are known to be related with angiogenesis [24,25]. Importantly, the generated iPS-ECs population appears to be heterogeneous that were enriched in iPS-ECs versus iPS cells. In the resting state ECs are ef- fective antigen-presenting cells. Correspondingly, iPS-ECs demonstrated functional enrichment for various membrane protein-encoding genes (Supplementary Fig. S4).

Annotation with GO "Biological Process" terms (Supplementary Fig. S5A) confirmed enrichment for characteristic vascular processes including vascular development (p = 1.45x10^{-6}), blood vessel morphogenesis (p = 9.08x10^{-6}) and regulation of cell adhesion (p = 9.71x10^{-6}) (Supplementary Fig. S5A). These processes identified enriched genes such as ENG, a novel EC specification gene [26] and FOXF1, a critical transcription factor that regulates embryonic vasculature development [27]. Enrichment patterns, therefore, correlate with the ability of iPS-ECs to form vascular structures. Furthermore, annotation of data with GO "Cellular Component" terms revealed enrichment for genes located in the extracellular region of the cell, including genes with roles in EC lineage specification and function (Supplementary Fig. S5B). Examples included FGFS, TGF-β1, ANGPT2 and ESM1. Based on these analyses, iPS-ECs possess transcriptomic profiles that will allow them to engage in a vast array of endothelial-related functions. Interestingly, the RNA-Seq analysis has revealed a high expression level of the gene ESM1 in iPS-ECs compared to iPS cells, as the Volcano plot shows in Figure 2H. As such, ESM1 held the potential to be an important candidate implicated in angiogenesis. Therefore, this study has further focused on the underlying mechanisms and function of ESM1 in iPS-ECs, with the ultimate goal to enrich the function of the derived iPS-ECs based on a fully-defined environment.

**ESM1 regulates EC marker expression in iPS-derived ECs**

To validate the RNA-Seq data and explore whether ESM1 is implicated in EC enrichment, real time PCR was performed to monitor expression levels of ESM1 mRNA in iPS cells, differentiating iPS-ECs at 3, 6, and 9 days of EC differentiation, and HUVECs. ESM1 mRNA levels significantly increased over time in iPS-ECs compared to the control iPS cells, reaching a peak at 9 days of differentiation, the levels of which were comparable to HUVECs (Fig. 3A). Seeing these results, we wanted to assess the role of ESM1 on iPS-ECs after differentiation and selection of CD144+ cells. When such iPS-ECs were visualised using immunofluorescent microscopy, ESM1 co-stained with EC markers KDR, CD144 and eNOS, indicating their concurrent expression (Fig. 3B). ESM1 was cloned in an overexpression vector-tagged with mCherry (EX-mCherry). iPS-ECs overexpressing ESM1 were compared to controls (Fig. 3C). Strikingly, significant increase in mRNA expression of EC markers KDR, CD144 and eNOS was observed 48 hours after transfection in mRNA level (Fig. 3D). In addition, ESM1 secretion levels, as detected by Luminex assay, were significantly increased in the cell culture media 48 hours after ESM1 overexpression compared to controls (Fig. 3E). 72 hours after ESM1 knockdown by lentiviral transduction, the mRNA levels of ESM1 and EC markers KDR, CD144 and eNOS were significantly decreased (Fig. 3F). This was also reflected in the cell culture media, in which significantly decreased ESM1 secretion levels were detected by Luminex (Fig. 3G). In addition, immunoblotting showed decreased protein levels in ESM1 and eNOS 72 hours after ESM1 knockdown (Fig. 3H), indicating its importance in regulating EC markers expression. Further support to the above notion is provided by additional data which shows that ESM1 overexpression in iPS-ECs induced the expression of angiogenic signalling genes such as uPA, Endothelin-1 and Angiopoietin-2, with a concurrent down-regulation of anti-angiogenic factors (Supplementary Fig. S6). Notably, ESM1 is also induced EC marker expression in early stages of EC differentiation (Supplementary Fig. S7).

**ESM1 regulates CX40 expression in iPS-ECs**

To shed further light into how ESM1 regulates EC markers, gene expression profiles were compared for iPS-ECs overexpressing ESM1 (EX-ESM1) and control iPS-ECs overexpressing mCherry (EX-mCherry). Generated RNA sequencing outputs were analysed using the CLC Genomics Workbench 10.0.1 (https://www.qiagenbioinformatics.com) to identify differential expression patterns, as described above (Fig. 4A, and Supplementary Fig. S8A-B). Interestingly, CX40 was one of the highly upregulated genes in the next-generation sequencing (NGS) in iPS-ECs (EX-ESM1) compared to control iPS-ECs (EX-mCherry) (Fig. 4A, and Supplementary Fig. S8A-B). In addition, iPS-ECs when compared with aortic ECs revealed similar expression levels of the aortic marker Ephrin B2 and the concurrent expression of ESM1 and CX40 (Supplementary Fig. S9). To confirm the RNA-Seq data, ESM1 was overexpressed in iPS-ECs, which resulted in significant increases in CX40 mRNA levels 48 hours after transfection with the EX-ESM1 plasmid compared to control (EX-mCherry) (Fig. 4B). On the contrary, when ESM1 was knocked down, a significant decrease in CX40 mRNA expression was observed 72 hours after lentiviral transduction.
with shESM1 compared to Non-Targeting control (shNT) (Fig. 4C). ESM1 overexpression in iPSCs resulted in significant increases in protein levels of ESM1, eNOS, CX40 and nuclear factor-kappa B (NFκB) 48 hours after transfection with EX-ESM1 plasmid compared to control (EX-mCherry) (Fig. 4D). When iPSCs were visualized using immunofluorescent microscopy, ESM1 co-stained with CX40 indicating their concurrent expression (Fig. 4E).

**ESM1 regulates EC marker expression in iPSCs through CX40**

ESM1 has been previously shown to increase the promoter activity and expression levels of NFκB [28], while putative transcription factor binding site research in the TRANSFAC database [29] [30] of the CX40 promoter revealed a binding site for NFκB. The above facts directed the notion that ESM1 induces the expression of CX40 in our cells possibly through NFκB induction. As a result, further experiments were performed to investigate how ESM1 regulates the expression of EC markers. 72 hours after lentiviral knockdown of CX40 (shCX40), CX40 and the EC markers eNOS and CD144 were significantly reduced at the mRNA level (Fig. 5A). In order to elucidate further the underlying mechanisms regulated by ESM1 in iPSCs and explore the link with CX40, CX40 was knocked down using shRNA and ESM1 was overexpressed 24 hours later. Quantitative Real Time PCR data (Fig. 5B) and western blots (Fig. 5C) revealed that the induction of EC markers mediated by ESM1 is ablated by CX40 knockdown, suggesting that in iPSCs ESM1 regulates EC marker expression through CX40. When the cells were transfected with ESM1, followed by NFκB inhibitor treatment, EC marker expression was ablated in the treated cells compared to controls (Fig. 5D). In addition, Luciferase assay was performed to assess CX40 promoter activity after ESM1 overexpression and NFκB inhibition, revealing diminished activity levels compared to controls (Fig. 5E). Immunofluorescent confocal imaging confirmed the parallel expression of CX40 and eNOS (Fig. 5F and Supplementary Fig. S10A), whereas co-immunoprecipitation (Co-IP) in cells stably expressing eNOS-GFP, confirmed the CX40 and eNOS-GFP interaction in (Fig. 5G). This data is in agreement with previous reports showing a role of CX40 in ECs in association with the EC marker eNOS [31,32]. Therefore, these experiments demonstrate that ESM1 regulates the expression of EC markers such as eNOS and CD144 through an association with CX40, an important EC gap junction channel component, possibly due to increased formation and stability of gap junctions, which are essential functional EC characteristics.

**ESM1 induces angiogenesis in vivo**

The next step was to validate the pivotal role of ESM1 in iPSCs enrichment and function in vivo. Human iPSCs were transfected with either Ex-mCherry plasmid or EX-ESM1 plasmid. After 48 hours, 1 million iPSCs overexpressing mCherry control (EX-mCherry) or 1 million iPSCs overexpressing ESM1 (EX-ESM1) were injected subcutaneously in SCID mice. Haematoxylin and eosin (H&E) staining of the Matrigel plugs with EX-mCherry and EX-ESM1 revealed that EX-ESM1 tissues formed defined vascular structures 7 days after the injection, in comparison to the control tissues where fewer vascular structures were observed (Fig. 6A and B). In addition, CD144 immunofluorescent staining of paraffin-embedded tissue sections confirmed the presence of differentiated cells in the in vivo vascular tubes (Fig. 6C). The EX-ESM1 tissues showed increased staining for CD144 and mCherry when compared to EX-mCherry control tissues (Fig. 6D).

**ESM1 significantly improved neovascularization and blood flow recovery in the hindlimb ischemic model**

To supplement the findings from our in vitro and in vivo angiogenesis data and to confirm further in vivo relevance of EC enrichment function through ESM1 signaling, additional experiments were performed to investigate whether ESM1 could induce angiogenesis in ischemic tissues and improve blood flow recovery. iPS-ECs (1x10^6) overexpressing control mCherry (EX-mCherry) or iPSCs overexpressing ESM1 (EX-ESM1) were injected intramuscularly into adductors of an ischemic model of SCID mice after induction of hindlimb ischemia in severe combined immunodeficiency (SCID) mice, as we have previously reported [33]. Laser Doppler images of blood flow (BF) in the lower limbs of mice in prone position 14 days post-injection of iPSC-EC showed that the cells enhanced neovascularization and supported significantly higher blood flow recovery in the ischemic limbs compared to the PBS controls. Notably, EX-ESM1-injected mice showed even higher recovery than mice injected with Ex-mCherry cells (Fig. 7A and B). Furthermore, limbs receiving EX-ESM1 cells displayed significantly higher capillary numbers in the musculature in comparison to their corresponding controls, as shown by positive staining of adductor muscle sections with CD144 (Fig. 7C, right panel). Finally, when adductor muscle sections from Ex-mCherry or EX-ESM1 injected animals were stained and quantified for mCherry and CD144, EX-ESM1 cells was found to exhibit an improved engraftment ability compared to controls (Fig. 7D and E), suggesting that EX-ESM1 cells display improved characteristic endothelial functions in vivo. Altogether, our findings suggest that ESM1 overexpression induces vessel formation in vivo, further supporting its vital role in the enrichment of iPSC-ECs and improving their function, which can, in turn, enhance vascular network development.

**DISCUSSION**

Cellular therapy involving the transplantation of cells to replace or repair damaged vascular tissues and ECs is a highly esteemed regenerative approach toward improving vascular function in patients with ischemic disease. This current study has revealed, for the first time, the role of ESM1 in enriching human iPSC-ECs and enhancing their neovascularization potential both in vitro and in vivo, advancing our understanding surrounding their reprogramming and differentiation.

ESM1 protein, also known as endocan, is a dermatan sulfate proteoglycan [34] which is primarily expressed in ECs of vascular tissues including capillaries and arterioles but can also be found in the ECs of other tissues such as human lung and kidney [35]. Its gene expression is regulated by cytokines, indicating its possible implication in endothelium-based disorders [36]. In addition, in recent studies, ESM1 has been identified as a specific biomarker of tip cells during angiogenesis [37] as
well as a simultaneous target and modulator of VEGF signalling in ECs [38].

This study established an optimised protocol for the generation of iPS-ECS from 1 ml of peripheral blood and used RNA-Seq to acquire a fresh insight into the mechanisms that underlie the process of differentiation to ECs and the maintenance of the endothelial profile. It was hypothesised that this approach would allow the identification of novel specific genes and pathways that are key for the generation of high quality mature ECs. More specifically, gene expression profiles were compared for iPS cells, iPS-ECS and HUVECs; iPS-ECS clustered more closely with HUVECs compared to iPS cells, confirming a dramatic shift away from pluripotency toward a specialised EC population. In addition, this generated EC population expressed both arterial and venous markers, with a greater propensity for the former subtype, as evidenced by the presence of Ephrin B2. This would allow for translational application in arterial vessels, as well as functional enrichment for various protein-encoding genes involved in vascular processes, development and blood vessel morphogenesis and EC lineage specification. Notably, using this model of iPS differentiation toward ECs, constitutive ESM1 expression was shown to be markedly upregulated during differentiation toward iPS-ECS suggesting a possible crucial role in enhancing this process. Indeed, subsequent in vitro experiments using overexpression or knockdown of ESM1 confirmed its role in regulating key EC markers in iPS-ECS.

A common limitation of iPS-ECS is their restricted proliferative capacity, which is also often accompanied by augmented instability and senescence [39], creating a large barrier in the path toward their clinical application in treating vascular disease. It is, thus, imperative that we expand our understanding and, thus, identify more key factors that may facilitate faster and safer EC generation. In addition, differentiated ECs can shift their phenotype away from the endothelial lineage after prolonged cell culture and exhibit an immature phenotype [12,40] with previous efforts focusing on preservation of EC stability and commitment [41,42]. Such observations of EC instability were also made in our study, in which ESM1 levels were reduced with increasing passages (after 15 passages) (Supplementary Fig. S10B). As a result, we demonstrated that ESM1 enhanced EC characteristics in iPS-ECS. Notably, iPS-ECS overexpressing ESM1 displayed greater functional properties in vitro and in vivo.

While investigating the mechanism by which ESM1 improved EC marker expression, it was noted that CX40 was significantly increased upon ESM1 overexpression. CX40 is a major connexin in most vascular ECs [43], a central component of gap junctions and important in communication [44] and harmonization of tissue responses [45–47].

In our study, further investigation on the relationship between ESM1 and CX40 revealed that CX40 acts downstream of ESM1. Particularly, we saw increased CX40 and amplified EC marker expression after ESM1 overexpression, which did not occur when we knocked down CX40. In agreement with our results, which showed increased EC marker expression and parallel expression of CX40 with eNOS, interaction of CX40 with eNOS has been shown to be important in the regulation of eNOS expression [31]. Indeed, CX40 is central in endothelial intercellular communication and EC homeostasis as it interacts with eNOS and has been shown to be expressed in close proximity to eNOS at cellular interfaces in ECs [48]. It has also been shown that ESM1 overexpression induces cell proliferation through induction of the NFKB pathway and that ESM1 interacts with NFKB and activates the NFKB promoter [28]. Notably, transcriptional binding analysis of the CX40 promoter identified a binding site for NFKB, suggesting that ESM1 induces the expression of CX40 in iPS-ECS, possibly through NFKB. In addition to the in vitro data, iPS-ECS overexpressing ESM1 induced enhanced angiogenesis in vivo 7 days after subcutaneous injection in SCID mice and ESM1 overexpression in iPS-ECS significantly improved neovascularization and blood flow recovery in the hindlimb ischemic model 14 days after intramuscular injection, demonstrating a crucial role of ESM1 in enhancing angiogenesis and neovascularization.

In conclusion, our data noticeably demonstrate that IPS cell generation and further iPS-ECS differentiation can be easily achieved using non-integrating methodology from a small amount of blood, whilst also revealing a vital role for ESM1 in improving EC enrichment and function. More particularly, ESM1 enhances CX40 expression improving, in turn, the expression of EC markers such as eNOS in iPS-ECS. The schematic diagram of the proposed mechanism is shown in the Graphical Abstract. This new approach for enhancing EC function of iPS-ECS derived from a very small amount of blood through cell reprogramming and ESM1 signalling could consequently improve our understanding of the molecular mechanisms involved in the process, and greatly increase the functionality and therapeutic potential of iPS-ECS in the clinic. This can, in turn, prove tremendously important in the advancement of patient-specific therapy, especially in regard to the treatment of EC dysfunction-based vascular disease.

### Acknowledgments

This work was supported by Grants from BBSRC and the British Heart Foundation. We also like to thank Kiran McLoughlin for his support with the Flow Cytometer.

### Declaration of Interests

The authors declare no competing financial interests.

### Authors Contributions

Marta Vilà-González & Sophia Kelaini: Conception and design, Collection and/or assembly of data, Data analysis and interpretation, Manuscript writing; Corey Magee: Collection and/or assembly of data; Rachel Caines: Collection and/or assembly of data; David Campbell: Collection and/or assembly of data; Magdalini Eleftheriadou: Collection and/or assembly of data; Amy Cochrane: Collection and/or assembly of data; Daiana Drehmer: Collection and/or assembly of data; Marianna Tsi-faki: Collection and/or assembly of data; Karla O’Neill: Collection and/or assembly of data; Edoardo Pedrini: Collection and/or assembly of data; Chunbo Yang: Collection and/or assembly of data; Reinhold Medina: Provision of study material; Denise McDonald: Provision of study material, Final approval of manuscript; David Simpson: Collection and/or assembly of data, Final approval of manuscript; Anna
Zampetaki: Provision of study material, Final approval of manuscript; Lingfang Zeng: Provision of study material, Final approval of manuscript; David Grieve: Provision of study material, Final approval of manuscript; Noemi Lois: Provision of study material, Final approval of manuscript; Alan W Stitt: Provision of study material, Final approval of manuscript; Andriana Margariti: Conception and design, Collection and/or assembly of data, Data analysis and interpretation, Manuscript writing, Financial support, Final approval of manuscript.

References

1. Cade WT. Diabetes-related microvascular and macrovascular diseases in the physical therapy setting. Phys Ther 2008;88: 1322–1335.
2. Mohammadi K, Woodward M, Marre M et al. Comparative effects of microvascular and macrovascular disease on the risk of major outcomes in patients with type 2 diabetes. Cardiovasc Diabetol 2017;16:95.
3. Cochrane A, Kelaini S, Tsifaki M et al. Quaking is a key regulator of endothelial cell differentiation, neovascularization, and angiogenesis. Stem Cells 2017;35: 952–966.
4. Rufaihah AJ, Huang NF, Jame S et al. Endothelial cells derived from human ipscs increase capillary density and improve perfusion in a mouse model of peripheral arterial disease. Arterioscler Thromb Vasc Biol 2011;31:e72–e79.
5. Giordano S, Zhao X, Chen YF et al. Induced pluripotent stem cell-derived endothelial cells overexpressing interleukin-8 receptors a/b and/or c-chemokine receptors 2/S inhibit vascular injury response. Stem Cells Translational Medicine 2017;6: 1168–1177.
6. Orlova VV, Drabsch Y, Freund C et al. Functionality of endothelial cells and pericytes from human pluripotent stem cells demonstrated in cultured vascularplexus and zebrafish xenografts. Arterioscler Thromb Vasc Biol 2014;34:177–186.
7. Kurokawa YK, Yin RT, Shang MR et al. Human induced pluripotent stem cell-derived endothelial cells for three-dimensional microphysiological systems. Tissue Eng Part C Methods 2017;23:474–484.
8. Singh VK, Kalsan M, Kumar N et al. Induced pluripotent stem cells: Applications in regenerative medicine, disease modeling, and drug discovery. Frontiers in Cell and Developmental Biology 2015;3:2.
9. Wu SM, Hochdinger L. Harnessing the potential of induced pluripotent stem cells for regenerative medicine. Nat Cell Biol 2011; 13:497–505.
10. Kelaini S, Cochrane A, Margariti A. Direct reprogramming of adult cells: Avoiding the pluripotent state. Stem cells and cloning: advances and applications 2014;7:19–29.
11. Collado MS, Cole BK, Figler RA et al. Exposure of induced pluripotent stem cell-derived vascular endothelial and smooth muscle cells in coculture to hemodynamics induces primary vascular cell-like phenotypes. Stem Cells Translational Medicine 2017;6: 1673–1683.
12. Cheng Z, Verma SK, Losordo DW et al. Reprogrammed human endothelial cells. Circ Res 2017;120:756.
13. Harding A, Cortez-Toledo E, Magnner Nataly L et al. Highly efficient differentiation of endothelial cells from pluripotent stem cells requires the mapk and the pi3k pathways. Stem Cells 2017;35:909–919.
14. Sriman G, Tan JY, Islam I et al. Efficient differentiation of human embryonic stem cells to arterial and venous endothelial cells under feeder- and serum-free conditions. Stem cell research & therapy 2015;6:261.
15. Rufaihah AJ, Huang NF, Kim J et al. Human induced pluripotent stem cell-derived endothelial cells exhibit functional heterogeneity. American journal of translational research 2013;5:21–35.
16. White MP, Rufaihah AJ, Liu L et al. Limited gene expression variation in endothelial cells and induced pluripotent stem cell-derived endothelial cells. Stem cells (Dayton, Ohio) 2013;31:92–103.
17. Bao X, Lian X, Dunn KK et al. Chemically-defined differentiation of human pluripotent stem cells to endothelial progenitor cells. Stem Cell Res 2015;15: 122–129.
18. Abu El-Asrar AM, Nawaz MI, De Hertogh G et al. The angiogenic biomarker endocan is upregulated in proliferative diabetic retinopathy and correlates with vascular endothelial growth factor. Curr Eye Res 2015; 40:321–331.
19. Balamir I, Ates I, Topcuoglu C et al. Association of endocan, ischemia-modified albumin, and hscrp levels with endothelial dysfunction in type 2 diabetes mellitus. Angiology 2013;73:1274–1281.
20. Takahashi K, Tanabe K, Ohnuki M et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007;131:861–872.
21. Dowey SN, Huang X, Chou B-K et al. Generation of integration-free human induced pluripotent stem cells from postnatal blood mononuclear cells by plasmid vector expression. Nat Protoc 2012;7:2013.
22. Chou B-K, Mali P, Huang X et al. Efficient human iPS cell derivation by a non-integrating plasmid from blood cells with unique epigenetic and gene expression signatures. Cell Res 2011;21:518.
23. Bazzoni G, Dejana E. Endothelial cell-to-cell junctions: Molecular organization and role in vascular homeostasis. Physiol Rev 2004;84:869–901.
24. Yamashita H, Shimizu A, Kato M et al. Growth/differentiation factor-5 induces angiogenesis in vivo. Exp Cell Res 1997;235: 218–226.
25. Rodriguez-Grande B, Varghese L, Molina-Holgado F et al. Pentraxin 3 mediates neurogenesis and angiogenesis after cerebral ischaemia. J Neuroinflammation 2015;12:15.
26. Banerjee S, Dhara SK, Bacmanowo M. Endoglin is a novel endothelial cell specification gene. Stem Cell Res 2012;8:85–96.
27. Ren X, Ustian V, Pradhan A et al. Foxf1 transcription factor is required for formation of embryonic vasculature by regulating vegf signaling in endothelial cells. Circ Res 2014; 115:709–720.
28. Kang YH, Ji NY, Han SR et al. Esm-1 regulates cell growth and metastatic process through activation of nf-kappab in colorectal cancer. Cell Signal 2012;24:1940–1949.
29. Messegue X, Escudero R, Farre D et al. Detection of known transcription regulatory elements using species-tailored searches. Bioinformatics (Oxford, England) 2002;18:333–334.
30. Farré D, Roset R, Huerta M et al. Identification of patterns in biological sequences at the algen server: Promo and malign. Nucleic Acids Res 2003;31: 363–365.
31. Le Gal L, Alonso F, Mazzolai L et al. Interplay between connexin40 and nitric oxide signaling during hypertension. Hypertension 2015;65:910–915.
32. Alonso F, Bootin FX, Beny JL et al. Loss of connexin40 is associated with decreased endothelium-dependent relaxations and enos levels in the mouse aorta. Am J Physiol Heart Circ Physiol 2010;299:H1365–H1373.
33. Kelaini S, Vila-Gonzalez M, Caines R et al. Follistatin-like 3 enhances the function of endothelial cells derived from pluripotent stem cells by facilitating beta-catenin nuclear translocation through inhibition of glycosynthetic kinase-3beta activity. Stem Cells 2018.
34. Kali A, Shetty KSR. Endocan: A novel circulating proteoglycan. Indian Journal of Pharmacology 2014;46:579–583.
35. Yang J, Yang Q, Yu S et al. Endocan: A new marker for cancer and a target for cancer therapy. Biomedical Reports 2015;3: 279–283.
36. Kechagia M, Papasotiropoulos I, Gourgoulians KI. Endocan and the respiratory system: A review. Int J Chron Obstruct Pulmon Dis 2016;11:3179–3187.
37. del Toro R, Probst C, Mathivet T et al. Identification and functional analysis of endothelial tip cell-enriched genes. Blood 2010;116:4025–4033.
38. Rocha SF, Schiller M, Jing D et al. Esm1 modulates endothelial tip cell behavior and vascular permeability by enhancing vegf bioavailability. Circ Res 2014;115:581–590.
39. Jiang B, Jen M, Perrin L et al. Sirt1 overexpression maintains cell phenotype and function of endothelial cells derived from induced pluripotent stem cells. Stem Cells Dev 2015;24:2740–2745.
40 Kokudo T, Suzuki Y, Yoshimatsu Y et al. Snail is required for tgfβ-induced endothelial-mesenchymal transition of embryonic stem cell-derived endothelial cells. J Cell Sci 2008;121:3317–3324.
41 James D, Nam HS, Seandel M et al. Expansion and maintenance of human embryonic stem cell-derived endothelial cells by tgfβ inhibition is id1 dependent. Nat Biotechnol 2010;28:161–166.
42 Kusuma S, Peijnenburg E, Patel P et al. Low oxygen tension enhances endothelial fate of human pluripotent stem cells. Arterioscler Thromb Vasc Biol 2014;34:913–920.
43 Inai T, Mancuso MR, McDonald DM et al. Shear stress-induced upregulation of connexin 43 expression in endothelial cells on upstream surfaces of rat cardiac valves. Histochem Cell Biol 2000;122:477–483.
44 Kanter HL, Saffitz JE, Beyer EC. Molecular cloning of two human cardiac gap junction proteins, connexin40 and connexin45. J Mol Cell Cardiol 1994;26:861–868.
45 Meens MJ, Alonso F, Le Gal L et al. Endothelial connexin37 and connexin40 participate in basal but not agonist-induced no release. Cell Communication and Signaling : CCS 2015;13(3).
46 Laird DW. The gap junction proteome and its relationship to disease. Trends Cell Biol 2010;20:92–101.
47 Agullo-Pascual E, Cerrone M, Delmar M. Arrhythmogenic cardiomyopathy and brugada syndrome: Diseases of the connexome. FEBS Lett 2014;588:1322–1330.
48 Pfenniger A, Derouette JP, Verma V et al. Gap junction protein cx37 interacts with endothelial nitric oxide synthase in endothelial cells. Arterioscler Thromb Vasc Biol 2010;30:827–834.
Figure 1. Efficient generation of integration-free iPS cells from peripheral blood mononuclear cells in 9 days: (A) Schematic flow diagram depicting the flow from 1 ml blood sample to iPS cells and iPS-ECs. (B) Phase contrast image showing the typical appearance of iPS cells colonies. Immunofluorescence assay for pluripotency markers Oct4, TRA-1-60, Lin28 and CDy1. Nuclei are counterstained with DAPI. Scale bars are 100 μm except for the left images where they are 200 μm. (C) Real Time PCR showing the mRNA expression levels of Oct4, Lin28 and Nanog in MNCs and iPS cells. Data were normalised to GAPDH. (D) Western blot showing TRA-1-60, Oct4 and Lin28 protein expression in MNCs and iPS cells. GAPDH was used as a loading control to correct for protein loading. (E) Haematoxylin and eosin (H&E) staining of iPS cells-associated teratoma formation in vivo following subcutaneous injection into SCID (severe combined immunodeficiency) mice. The data presented are representative or means (±SEM) of three independent experiments.
Figure 2. Differentiation of human iPS cells to iPS-ECs: (A) Schematic diagram depicting the protocol for differentiating iPS cells to iPS-ECs. (B) Phase contrast imaging showing the characteristic morphology of iPS-ECs. Scale bar = 200 μm. (C) Real Time PCR showing how mRNA expression levels for the endothelial markers KDR, CD144 and eNOS change in iPS-ECs during endothelial differentiation from day 0 to 6 and 3 days after CD144 selection. (Data are means ±SEM [n = 3], *p < .05, ***p < .001). (D) Flow cytometry analysis showing the percentage of cells that express CD144 before selection compared to cells stained with isotype control. (E) Western blot showing the protein expression of CD144 and Oct4 in iPS cells and iPS-ECs after differentiation and CD144+ selection. (F) Immunofluorescent staining for CD144 (top left), CD31 (top right) and ZO-1 (middle left). Junctional markers are stained green. Nuclei are counterstained with DAPI (blue). Images depicting the functional qualities of iPS-ECs – acetylated (Ac)-LDL uptake (red) (middle right), in vitro tube formation assay on Matrigel (bottom left) and immunofluorescent staining for CD144 (green) in in vitro capillary-like structures (bottom right). Nuclei are counterstained with DAPI (blue). Scale bars are all 50 μm except for the bottom images, where it is 200 μm. (G) Comparison of overall gene expression profiles for iPS cells, iPS-ECs and HUVECs: Heat Map (Manhattan distance, single linkage) showing hierarchical clustering results for iPS cells, iPS-ECs and HUVECs replicates. Normalized expression values were used for hierarchical clustering. In this heat map, red represents genes that are more highly expressed within a given cell line, while blue represents genes that are expressed at lower levels within a defined cell line. A, B and C refer to group replicates. (H) Volcano Plot of differentially expressed genes in iPS cells versus iPS-ECs depicting statistical significance as log10 (p-values) on the y-axis plotted against fold change as log2 (fold change) on the x-axis. Genes with greater expression in iPS-ECs are plotted on the right side of the plot. The data presented are representative or means (±SEM) of three independent experiments.
Figure 3. ESM1 regulates EC marker expression in ECs from iPS cells and ESM1 signalling (A) Real Time PCR data showing comparison of ESM1 mRNA expression levels between iPS cells, iPS-ECs (at 3, 6, and 9 days of EC differentiation) and HUVECs. (Data are means ±SEM (n = 3), *p < .05, **p < .01). (B) Immunofluorescent images showing co-staining of ESM1 (red), EC markers KDR, eNOS, CD144 (green) and DAPI (blue). Scale bars are 50 μm. (C) Representative immunofluorescent images of iPS-ECs overexpressing EX-mCherry (red) and EX-ESM1 (red) 48 hours after transfection with the corresponding plasmids. Scale bars are 100 μm. (D) 48 hours after ESM1 overexpression, a significant increase in mRNA expression of EC markers KDR, CD144 and eNOS was observed. (Data are means ±SEM [n = 3], **p < .01, ***p < .001). (E) ESM1 protein concentration levels 48 hours after ESM1 overexpression were significantly increased in the cell culture media compared to control, as detected by Luminex assay. (Data are means ±SEM [n = 3], *p < .05). (F) ESM1 knockdown 72 hours after lentiviral transduction with shESM1, compared to Non-Targeting control (shNT), resulted in significantly decreased mRNA levels of ESM1 and EC markers KDR, CD144 and eNOS. (Data are means ±SEM [n = 3], *p < .01, ***p < .001). (G) ESM1 protein concentration levels 72 hours after ESM1 knockdown were significantly decreased in the cell culture media compared to control, as detected by Luminex. (Data are means ±SEM [n = 3], *p < .05). (H) Western blot (left panel) and corresponding densitometry (right panel) showing decreased protein levels in ESM1 and eNOS in iPS-ECs with ESM1 knockdown. The data presented are representative or means (±SEM) of three independent experiments. (Data are means ±SEM [n = 3], *p < .05, **p < .01).
Figure 4. ESM1 regulates CX40 expression. (A) Heat map of RNA level differences between iPS-ECs overexpressing ESM1 (EX-ESM1) compared to control iPS-ECs (EX-mCherry). (B) Overexpression of ESM1 leading to a significant increase in CX40 48 hours after transfection with EX-ESM1 compared to control (EX-mCherry). (Data are means ±SEM [n = 3], *p < .05, **p < .01). (C) Knockdown of ESM1 leading to a significant decrease in CX40 72 hours after lentiviral transduction with shESM1 compared to Non-Targeting control (shNT). (Data are means ±SEM [n = 3], **p < .01, ***p < .001). (D) Western blots showing increased protein levels in ESM1, eNOS, CX40 and NFkB 48 hours after ESM1 overexpression. (E) Immunofluorescent images of cells co-stained with ESM1 (red), CX40 (green) and DAPI (blue). Scale bars are 50 μm. The data presented are representative or means (±SEM) of three independent experiments.
Figure 5. **ESM1 regulates EC marker expression through CX40.** 72 hours after lentiviral knockdown of CX40 (shCX40) in iPS-ECs, CX40, eNOS and CD144 were significantly reduced at the mRNA level, but not ESM1. (Data are means ±SEM [n = 3] ***p < .001). (B-C) CX40 was knocked down by shRNA on day 3 of EC differentiation, and ESM1 was overexpressed on day 4. (B) Real Time PCR data and (C) western blots reveal the induction of EC markers mediated by ESM1 is ablated by CX40 knockdown. (Data are means ±SEM [n = 3] *p < .05, ***p < .001). (D) Cells were treated with NFKB inhibitor prior to ESM1 overexpression: CX40, CD144 and eNOS expression mediated by ESM1 was ablated after NFKB inhibition. (Data are means ±SEM [n = 3], *p < .05, ***p < .001). (E) Luciferase assay for CX40 reporter in cells treated with NFKB inhibitor prior to ESM1 overexpression. (Data are means ±SEM [n = 3], *p < .05). (F) Immunofluorescent confocal image showing co-staining of CX40 (red), eNOS (green) and DAPI (blue) in cells overexpressing eNOS-GFP. Scale bars: 25 μm (G) Co-IP showing CX40 and eNOS-GFP interaction. The data presented are representative or means (±SEM) of three independent experiments.
Figure 6. ESM1 improves angiogenesis and CD144 expression in vivo. Human iPS-ECs overexpressing either mCherry (EX-mCherry) or ESM1 (EX-ESM1) were injected subcutaneously in SCID mice 48 hours after transfection. (A) H&E staining of EX-mCherry and EX-ESM1 Matrigel plugs. EX-ESM1 tissues significantly formed well-defined vascular structures at 7 days in comparison to the control tissues where fewer vascular structures were observed. (B) Quantified capillary density. (Data are means ± SEM, n = 3, **p < .01). Quantification from 10 random microscopic fields at x40, scale bars: 50 μm. Quantiﬁed capillary density expressed as capillary number per mm². (C) Paraffin sections of CD144 immunofluorescent staining conﬁrmed the presence of differentiated cells in the in vivo vascular tubes. (D) Quantified capillary density based on doubly-stained CD144- and mCherry- cells. (Data are means ± SEM, n = 3, **p < .01. Quantification from 10 random microscopic fields at x40, scale bars: 50 μm). Quantiﬁed capillary density expressed as capillary number per mm². The data presented are representative or means (±SEM) of three independent experiments.
Figure 7. ESM1 significantly improved neovascularization and blood flow recovery in the hindlimb ischemic model. (A) Laser Doppler images of blood flow (BF) in the lower limbs of mice in prone position control after treatment with control iPS-ECs (PBS-CTL or iPS-ECs overexpressing EX-mCherry) and iPS-ECs overexpressing ESM1 (EX-ESM1). (B) BF recovery in the ischemic foot (calculated as a percentage ratio between ischemic foot BF and the contralateral foot) for each of the conditions. Statistical analysis shows significantly higher BF recovery in the EX-ESM1 mice at 14 days in comparison with controls; Bonferroni post test (to one way ANOVA) confirms significant difference after 14 days between the control iPS-ECs and EX-ESM1; (Data are means ± SEM, n = 3, *p < .05). (C) Sections of adductor muscles of each condition were stained with CD144 antibody (left and middle scale bars are 50 μm, right scale bar is 100 μm) and capillary density was quantified and expressed as capillary number per mm² (D) (Data are means ± SEM, n = 3, *p < .05). (E) Quantified capillary density of CD144 and mCherry doubly-stained cells. (Data are means ± SEM, n = 3, **p < .01. Quantification from 10 random microscopic fields at x40). The data presented are representative or means (±SEM) of three independent experiments.
Graphical abstract

From a small amount of blood, human iPS cells are generated in a fast and robust approach and then differentiated to iPS-ECs. This novel approach for enhancing iPS-ECs through ESM1 could consequently improve our understanding of the molecular mechanisms involved in the process, and greatly increase the efficiency and generation of iPS-ECs as therapeutic tools to the treatment of EC dysfunction-based vascular disease.